Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods

Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14, and ASPH to identify patients who may benefit from treatment with LP-184, marking a significant step in precision oncology.

Lantern said its RADR artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. To view the full press release, visit https://ibn.fm/LRGUo.

This patent allowance underscores the potential of Lantern's AI-driven approach to drug development. By leveraging the RADR platform to identify biomarker signatures, the company aims to match patients with therapies most likely to be effective, thereby improving outcomes and reducing trial costs. The three-gene signature (PTGR1, PTPN14, ASPH) serves as a predictive biomarker for LP-184, an acylfulvene derivative that targets DNA repair pathways in cancer cells.

The implications of this announcement are broad. For patients with hard-to-treat cancers like ovarian and liver cancer, the availability of a biomarker-guided therapy could lead to more effective treatment options. For Lantern, the patent strengthens its intellectual property portfolio and supports the company's strategy to develop precision oncology drugs. The RADR platform's ability to derive such signatures from complex genomic data highlights the growing role of artificial intelligence in pharmaceutical research.

Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics. Additionally, Lantern's withZeta.ai platform is now commercially available as a subscription-based research platform. For more information, visit the company's newsroom at https://ibn.fm/LTRN.